Icotrokinra led to high rates of skin clearance in patients with scalp and genital psoriasis, according to results from the ICONIC-TOTAL study.

The trial enrolled patients aged 12 years and older whose specific skin sites were affected by plaque psoriasis of at least moderate severity. The data were part of a presentation at the ongoing ...

The phase 3 ICONIC-TOTAL trial has been evaluating the drug in adults and adolescents aged 12 years and older with at least moderate plaque psoriasis affecting high-impact skin sites. It is estimated ...

Icotrokinra is the first investigational, oral peptide designed to selectively block interleukin-23 receptors in people with moderate to severe plaque psoriasis, ulcerative colitis and other ...

Last December, it secured FDA approval for the treatment of adult patients with plaque psoriasis, regardless of the severity of their symptoms, making it an option for all the estimated eight ...

J&J is hoping to show that the peptide drug can be a more patient-friendly alternative to injectable biologics for plaque psoriasis, including drugs working on IL-23, such as J&J's own Tremfya ...

It then crossed a grassy shoulder and dropped roughly 30 feet onto Southeast 38th St., Trooper Rick Johnson told Fox News Digital. "This Humvee Tonic Trailer was traveling eastbound on Interstate ...

In 2022, a drug called deucravacitinib was approved by the U.S. Food and Drug Administration to treat psoriasis. This medication targets TYK2 in a way that stops its ability to relay harmful ...

From November through April, snow totals reached 231.4 inches, or just under 20 feet, according to the state park. The flow at the Upper Falls is now at an impressive 32,000 gallons per second ...